Danske Bank A/S Biomarin Pharmaceutical Inc Transaction History

Danske Bank A/S

  • $1.95 Trillion
  • Q3 2025

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 19, 2025
BUY
$52.62 - $61.93 $6.08 Million - $7.16 Million
115,624 New
115,624 $6.26 Million
Q2 2025

Dec 18, 2025
BUY
$54.08 - $68.32 $1.29 Million - $1.63 Million
23,930 Added 28.3%
108,501 $5.96 Million
Q1 2025

Dec 18, 2025
SELL
$61.25 - $72.83 $1.9 Million - $2.26 Million
-31,053 Reduced 26.86%
84,571 $5.98 Million

Others Institutions Holding BMRN

# of Institutions
664
Shares Held
184M
Call Options Held
1.48M
Put Options Held
957K
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $10.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Danske Bank A/S Portfolio

Follow Danske Bank A/S and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Danske Bank A/S, based on Form 13F filings with the SEC.

News

Stay updated on Danske Bank A/S with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email